Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at Stanford Cancer Institute, starting in spring 2026. He will lead the Early Drug Development Program to improve access to innovative treatments through phase 1 trials tailored by patients' biological markers. An internationally recognized leader in precision oncology, Dr. Subbiah has directed numerous trials and contributed significantly to advancing tumor-agnostic therapies, aiming to keep patients at the core of treatment advancements.